Gilead Sciences | GILD - Market Capitalization


Gilead Sciences reported $181.02B in Market Capitalization this September of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 444.6B 59.91B Jun/2026
ALKERMES USD 8.73B 2.85B Jun/2026
Alnylam Pharmaceuticals USD 40.19B 3.96B Jun/2026
Amgen USD 195.44B 5.55B Jun/2026
Biogen USD 31.9B 5B Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 117.66B 6.17B Jun/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 1.13T 260.54B Jun/2026
Gilead Sciences USD 156.86B 16.13B Jun/2026
GlaxoSmithKline GBP 80.14B 3.66B Jun/2026
Glaxosmithkline GBP 109.29B 9.36B Mar/2026
Incyte USD 22.65B 3.92B Jun/2026
J&J USD 611.36B 32.21B Jun/2026
Merck USD 317.37B 20.27B Jun/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Novartis USD 240.59B 67.17B Jun/2026
Pfizer USD 138.44B 15.37B Jun/2026
Regeneron Pharmaceuticals USD 65.37B 16.31B Jun/2026
Sanofi EUR 91.15B 9.12B Jun/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
United Therapeutics USD 23B 2.19B Jun/2026
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026